Erratum: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts (Endocrine-Related Cancer (2023) 21:5 (739–753) DOI: 10.1530/ERC-14-0245);GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts

Endocrine-Related Cancer

Volumn 21, Issue 5, 2014, Pages 739-753

  De Marco, Paola ^a   Romeo, Enrica ^a   Vivacqua, Adele ^a   Malaguarnera, Roberta ^c   Abonante, Sergio ^b   Romeo, Francesco ^b   Pezzi, Vincenzo ^a   Belfiore, Antonino ^c   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b Regional Hospital   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cancer cells; Cancer associated fibroblasts (CAFs); Estrogen; GPER1; Insulin

Indexed keywords

ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUCOSE; GPER PROTEIN, HUMAN; GPR30 PROTEIN, MOUSE; INSULIN; PROTEIN C FOS; TRANSCRIPTION FACTOR AP 1;

ANIMAL; CELL CULTURE; CELL CYCLE; CELL LINE; CELL MOTION; DRUG EFFECTS; FIBROBLAST; GENETICS; HUMAN; METABOLISM; MOUSE; NEOPLASM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; FIBROBLASTS; GLUCOSE; HUMANS; INSULIN; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; TRANSCRIPTION FACTOR AP-1;

EID: 84907524361     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0245e     Document Type: Erratum

References (59)

1. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Andó S et al. 2007 G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Research 67 1859-1866. (doi:10.1158/0008-5472.CAN-06-2909).
2. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, Lappano R, Pandey DP, Picard D, Mauro L et al. 2008 Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 8 3799-3808. (doi:10.1210/en.2008-0117).
3. Alonso A, Fernández R, Moreno M, Ordóñez P, González-Pardo H, Conejo NM, Díaz F & González C 2006 Positive effects of 17β-estradiol on insulin sensitivity in aged ovariectomized female rats. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 61 419-426. (doi:10.1093/gerona/61.5.419).
4. Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER et al. 2010 GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Research and Treatment 123 51-58. (doi:10.1007/s10549-009-0631-7).
5. Balhuizen A, Kumar R, Amisten S, Lundquist I & Salehi A 2010 Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice. Molecular and Cellular Endocrinology 320 16-24. (doi:10.1016/j.mce.2010.01.030).
6. Bartella V, De Marco P, Malaguarnera R, Belfiore A & Maggiolini M 2012 New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cell Signalling 24 1515-1521. (doi:10.1016/j.cellsig.2012.03.012).
7. Belfiore A 2007 The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Current Pharmaceutical Design 13 671-686. (doi:10.2174/138161207780249173).
8. Belfiore A & Malaguarnera R 2011 Insulin receptor and cancer. Endocrine-Related Cancer 18 R125-R147. (doi:10.1530/ERC-11-0074).
9. Catsburg C, Gunter MJ, Chen C, Cote ML, Kabat GC, Nassir R, Tinker L, Wactawski-Wende J, Page DL & Rohan TE 2014 Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease. Cancer Research 74 3248-3258. (doi:10.1158/0008-5472.CAN-13-3514).
10. Chu CY, Chang CC, Prakash E & Kuo ML 2008 Connective tissue growth factor (CTGF) and cancer progression. Journal of Biomedical Science 15 675-685. (doi:10.1007/s11373-008-9264-9).
11. Cohen DH & Le Roith D 2012 Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocrine-Related Cancer 19 F27-F45. (doi:10.1530/ERC-11-0374).
12. De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A & Maggiolini M 2013 HIF-1a/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Research 4 R64. (doi:10.1186/bcr3458).
13. De Francesco EM, Pellegrino M, Santolla MF, Lappano R, Ricchio E, Abonante S & Maggiolini M 2014 GPER mediates activation of HIF-1a/VEGF signaling by estrogens. Cancer Research 74 1-12. (doi:10.1158/0008-5472.CAN-13-3590).
14. De Marco P, Bartella V, Vivacqua A, Lappano R, Santolla MF, Morcavallo A, Pezzi V, Belfiore A & Maggiolini M 2013 Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene 6 678-688. (doi:10.1038/onc.2012.97).
15. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI, Yamaguchi Y, Hayashi S, Sklar LA et al. 2011 Identification of a GPER/GPR30 antagonist with improved estrogen receptor counter-selectivity. Journal of Steroid Biochemistry and Molecular Biology 127 358-366. (doi:10.1016/j.jsbmb.2011.07.002).
16. Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R & McTiernan A 2011 Associations of insulin resistance and adiponectin with mortality in women with breast cancer. Journal of Clinical Oncology 29 32-39. (doi:10.1200/JCO.2009.26.4473).
17. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A & Vigneri R 1999 Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 19 3278-3288. (doi:10.1210/en.2009-0377).
18. Garrido P, Morán J, Alonso A, González S & González C 2013 17β-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells. Endocrinology 154 1979-1989. (doi:10.1210/en.2012-1558).
19. Hall JM, Couse JF & Korach KS 2001 The multifaceted mechanisms of estradiol and estrogen receptor signaling. Journal of Biological Chemistry 276 36869-36872. (doi:10.1074/jbc.R100029200).
20. Hess J, Angel P & Schorpp-Kistner M 2004 AP-1 subunits: quarrel and harmony among siblings. Journal of Cell Science 117 5965-5973. (doi:10.1242/jcs.01589).
21. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, Roessner A, Costa SD & Kalinski T 2011 G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Research and Treatment 128 457-466. (doi:10.1007/s10549-011-1584-1).
22. Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, Ho GY, Rodriguez BL, Shikany JM, Strickler HD, Vitolins MZ et al. 2009 Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. International Journal of Cancer 125 2704-2710. (doi:10.1002/ijc.24609).
23. 2+ signaling and phosphatidylinositol 4,5-bisphosphate hydrolysis induced by Gq protein-coupled receptor agonists through an mTOR-dependent pathway. Endocrinology 148 3246-3257. (doi:10.1210/en.2006-1711).
24. Kumar R, Balhuizen A, Amisten S, Lundquist I & Salehi A 2011 Insulinotropic and antidiabetic effects of 17 b-estradiol and the GPR30 agonist G-1 on human pancreatic islets. Endocrinology 152 2568-2579. (doi:10.1210/en.2010-1361).
25. Lappano R & Maggiolini M 2012 G protein-coupled receptors: novel targets for drug discovery in cancer. Nature Reviews. Drug Discovery 10 47-60. (doi:10.1038/nrd3320).
26. Lappano R, Rosano C, Santolla MF, Pupo M, De Francesco EM, De Marco P, Ponassi M, Spallarossa A, Ranise A & Maggiolini M 2012 Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. Current Cancer Drug Targets 12 531-542. (doi:10.2174/156800912800673284).
27. Lappano R, De Marco P, De Francesco EM, Chimento A, Pezzi V & Maggiolini M 2013 Cross-talk between GPER and growth factor signaling. Journal of Steroid Biochemistry and Molecular Biology 137 50-56. (doi:10.1016/j.jsbmb.2013.03.005).
28. Liu S, Le May C, Wong WP, Ward RD, Clegg DJ, Marcelli M, Korach KS & Mauvais-Jarvis F 2009 Importance of extranuclear estrogen receptor-a and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 58 2292-2302. (doi:10.2337/db09-0257).
29. Liu S, Kilic G, Meyers MS, Navarro G, Wang Y, Oberholzer J & Mauvais-Jarvis F 2013 Oestrogens improve human pancreatic islet transplantation in a mouse model of insulin deficient diabetes. Diabetologia 56 370-381. (doi:10.1007/s00125-012-2764-1).
30. Madeo A & Maggiolini M 2010 Nuclear alternate estrogen receptor GPR30 mediates 17β-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Research 70 6036-6046. (doi:10.1158/0008-5472.CAN-10-0408).
31. Maggiolini M & Picard D 2010 The unfolding stories of GPR30, a new membrane-bound estrogen receptor. Journal of Endocrinology 204 105-114. (doi:10.1677/JOE-09-0242).
32. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D & Andò S 2004 The G proteinc-oupled receptor GPR30 mediates c-fos up-regulation by 17β-estradiol and phytoestrogens in breast cancer cells. Journal of Biological Chemistry 279 27008-27016. (doi:10.1074/jbc.M403588200).
33. Marchese S & Silva E 2012 Disruption of 3D MCF-12A breast cell cultures by estrogens - an in vitro model for ER-mediated changes indicative of hormonal carcinogenesis. PLoS ONE 7 e45767. (doi:10.1371/journal.pone.0045767).
34. Martensson UE, Salehi SA, Windahl S, Gomez MF, Swärd K, Daszkiewicz-Nilsson J, Wendt A, Andersson N, Hellstrand P, Grände PO et al. 2009 Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 150 687-698. (doi:10.1210/en.2008-0623).
35. Mizukami Y 2010 In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: from discovery to functions in vivo. Endocrine Journal 57 101-107. (doi:10.1507/endocrj.K09E-332).
36. Morcavallo A, Gaspari M, Pandini G, Palummo A, Cuda G, Larsen MR, Vigneri R & Belfiore A 2011 Research resource: new and diverse substrates for the insulin receptor isoform A revealed by quantitative proteomics after stimulation with IGF-II or insulin. Molecular Endocrinology 25 1456-1468. (doi:10.1210/me.2010-0484).
37. Moreno M, Ordonez P, Alonso A, Diaz F, Tolivia J & Gonzalez C 2010 Chronic 17β-estradiol treatment improves skeletal muscle insulin signaling pathway components in insulin resistance associated with aging. Age 32 1-13. (doi:10.1007/s11357-009-9095-2).
38. Pandey DP, Lappano R, Albanito L, Madeo A,MaggioliniM& Picard D 2009 Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO Journal 28 523-532. (doi:10.1038/emboj.2008.304).
39. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R & Belfiore A 2002 Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. Journal of Biological Chemistry 277 39684-39695. (doi:10.1074/jbc.M202766200).
40. Prossnitz ER & Barton M 2011 The G-protein-coupled estrogen receptor GPER in health and disease. Nature Reviews. Endocrinology 7 715-726. (doi:10.1038/nrendo.2011.122).
41. Prossnitz ER & Barton M 2014 Estrogen biology: new insights into GPER function and clinical opportunities. Molecular and Cellular Endocrinology 389 71-83. (doi:10.1016/j.mce.2014.02.002).
42. Prossnitz ER & Maggiolini M 2009 Mechanisms of estrogen signaling and gene expression via GPR30. Molecular and Cellular Endocrinology 308 32-38. (doi:10.1016/j.mce.2009.03.026).
43. Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco EM, Abonante S, Rosano C & Maggiolini M 2012 Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environmental Health Perspectives 120 1177-1182. (doi:10.1289/ehp.1104526).
44. Recchia AG, De Francesco EM, Vivacqua A, Sisci D, Panno ML, Andò S & Maggiolini M 2011 The G protein-coupled receptor 30 is up-regulated by hypoxia inducible factor-1a (HIF-1a) in breast cancer cells and cardiomyocytes. Journal of Biological Chemistry 286 10773-10782. (doi:10.1074/jbc.M110.172247).
45. Rosano C, Lappano R, SantollaMF, Ponassi M, Donadini A & Maggiolini M 2012 Recent advances in the rationale design of GPER ligands. Current Medicinal Chemistry 19 6199-6206. (doi:10.2174/092986712804485755).
46. Rose DP & Vona-Davis L 2012 The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocrine-Related Cancer 19 R225-R241. (doi:10.1530/ERC-12-0203).
47. Scaling AL, Prossnitz ER & Hathaway HJ 2014 GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Hormones & Cancer 3 146-160. (doi:10.1007/s12672-014-0174-1).
48. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R & Belfiore A 2002 In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 21 8240-8250. (doi:10.1038/sj.onc.1206058).
49. Sell C, Dumeni G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A & Baserga R 1994 Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Molecular and Cellular Biology 14 3604-3612. (doi:10.1128/MCB.14.6.3604).
50. Sharma G & Prossnitz ER 2013 Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic β-cells. Endocrinology 152 3030-3039. (doi:10.1210/en.2011-0091).
51. Sharma G, Hu C, Brigman JL, Zhu G, Hathaway HJ & Prossnitz ER 2013 GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state. Endocrinology 154 4136-4145. (doi:10.1210/en.2013-1357).
52. Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G, Contiero P, Schunemann HJ et al. 2012 Prospective study on the role of glucose metabolism in breast cancer occurrence. International Journal of Cancer 130 921-929. (doi:10.1002/ijc.26071).
53. Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjóld B, Sgroi DC, Skoog L, Stal O, Leeb-Lundberg LM et al. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. Breast Cancer Research and Treatment 145 61-71. (doi:10.1007/s10549-014-2936-4).
54. Vigneri P, Frasca F, Sciacca L, PandiniG&VigneriR 2009Diabetes and cancer. Endocrine-Related Cancer 16 1103-1123. (doi:10.1677/ERC-09-0087).
55. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S & Maggiolini M 2006a The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Molecular Endocrinology 20 631-646. (doi:10.1210/me.2005-0280).
56. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Andò S & Maggiolini M 2006b 17β Estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein coupled-receptor GPR30. Molecular Pharmacology 70 1414-1423. (doi:10.1124/mol.106.026344).
57. Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, Fuqua SA, Andò S & Maggiolini M 2009 G protein coupled receptor 30 expression is up-regulated by EGF and TGFα in estrogen receptor a-positive cancer cells. Molecular Endocrinology 23 1815-1826. (doi:10.1210/me.2009-0120).
58. Yamada K, Saito M, Matsuoka H & Inagaki N 2007 A real-time method of imaging glucose uptake in single, living mammalian cells. Nature Protocols 2 753-762. (doi:10.1038/nprot.2007.76).
59. 2+ oscillations in pancreatic cancer PANC-1 cells. Biochemical and Biophysical Research Communications 401 154-158. (doi:10.1016/j.bbrc.2010.09.036).